Median dosing interval and ocular events. (A-B) Post hoc analyses that included only treated patients who had BCVA of 20/25 or better in ≥1 eye at baseline in DREAMM-7 (n = 211; A) and DREAMM-8 (n = 137; B). The graph only shows the occurrence of bilateral 20/50 or worse BCVA changes, overall median of the average time between belamaf doses, and discontinuation of belamaf due to ocular events in each time interval while patients remained on belamaf treatment. The incidence rate at each time point is based on the number of patients who remained on treatment at that time point and does not reflect the overall risk of developing bilateral worsening of 20/50 or greater or discontinuing due to an ocular event at any time during belamaf treatment. The increased time between doses is due to AEs, including ocular events, and other non–AE-related reasons. This graph does not detail any efficacy parameter over time. ∗Median of average days between doses for each patient per interval was used and converted to weeks. ^†For DREAMM-7, events during the initial 2.5 years of treatment are shown due to limited number of patients at risk beyond this time point. ^‡For DREAMM-8, the first 2 years of treatment are shown due to limited number of patients at risk beyond this time point. CTCAE, Common Terminology Criteria for Adverse Events; IQR, interquartile range.